Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with ...

Coloplast’s FY 2024/25 financial guidance 1 of organic revenue growth at 8-9% and an EBIT margin before special items of around 28% is unchanged and already includes the divestment. This ...

On Wednesday, UBS analyst changed the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) from Sell to Neutral, maintaining a price target of DKK858.00. The revision follows a reassessment of ...

Investing.com -- UBS has revised its rating on Coloplast (CSE:COLOb) A/S, upgrading the Danish healthcare company to "neutral" from "sell." This revision reflects changes in market dynamics and a ...